Skip to main content
Erschienen in: Medical Oncology 2/2015

01.02.2015 | Original Paper

Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials

verfasst von: Wenmei Su, Zhennan Lai, Fenping Wu, Yanming Lin, Yanli Mo, Zhixiong Yang, Jiayuan Wu

Erschienen in: Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s. Although several studies have been conducted, the results remain controversial. Randomized controlled trials have an improved balance of confounding factors and reliable results. Thus, we performed a meta-analysis based on randomized controlled trials to gather more evidence of the effect of ifosfamide on neoadjuvant chemotherapy for patients with osteosarcoma of the extremity. An electronic search was conducted via the Internet retrieval system to identify eligible trials until September 2014. Odds ratios (ORs) and 95 % confidence interval (CI) were calculated to compare the results of ifosfamide and ifosfamide-free therapies. Four trials with a total of 1,378 patients were eligible for our meta-analysis. Overall, compared with neoadjuvant chemotherapy without ifosfamide, the use of ifosfamide had no advantage in terms of histological response to chemotherapy (cHR; OR 1.36; 95 % CI 0.90–2.03, P = 0.140), 5-year event-free survival (EFS; OR 1.16; 95 % CI 0.789–1.75, P = 0.464), and 5-year overall survival (OS; OR 1.06; 95 % CI 0.70–1.59, P = 0.794). However, improvement was noted in the rate of limb salvage (OR 4.06; 95 % CI 2.04–8.10, P < 0.001). Neoadjuvant chemotherapy with ifosfamide for patients with extremity osteosarcoma might not increase the cHR and exhibited no significant effect on either EFS or OS. However, ifosfamide therapy could significantly increase the rate of limb salvage for osteosarcoma of the extremity, which suggests that the preoperative use of ifosfamide could increase the success rate of limb salvage operation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670–8.PubMedCrossRef Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670–8.PubMedCrossRef
2.
Zurück zum Zitat van Dalen EC, van As JW, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev. 2011;5:CD006325.PubMed van Dalen EC, van As JW, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev. 2011;5:CD006325.PubMed
3.
Zurück zum Zitat Smelangd S, et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma. Acta Orthop. 2011;82:211–6.CrossRef Smelangd S, et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma. Acta Orthop. 2011;82:211–6.CrossRef
4.
Zurück zum Zitat Bacci G, et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group Pilot Study. J Chemother. 2002;14:198–206.PubMedCrossRef Bacci G, et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group Pilot Study. J Chemother. 2002;14:198–206.PubMedCrossRef
5.
Zurück zum Zitat Le Deley MC, et al. SFOP OS94: a randomized trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752–61.PubMedCrossRef Le Deley MC, et al. SFOP OS94: a randomized trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752–61.PubMedCrossRef
6.
Zurück zum Zitat Bacci G, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27:98–104.PubMedCrossRef Bacci G, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27:98–104.PubMedCrossRef
7.
Zurück zum Zitat Ferrari S, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30:2112–8.PubMedCrossRef Ferrari S, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30:2112–8.PubMedCrossRef
8.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic review and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.PubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic review and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.PubMedCrossRef
9.
Zurück zum Zitat Maxwell L, et al. Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol. 2006;33:2304–11.PubMed Maxwell L, et al. Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol. 2006;33:2304–11.PubMed
10.
Zurück zum Zitat Wells GA, et al. The Newcastle-Ottawa Scala (NOS) for assessing the quality of nonrandomized studies in meta-analyses, Ottawa Health Research Institute Web site. 2012. Wells GA, et al. The Newcastle-Ottawa Scala (NOS) for assessing the quality of nonrandomized studies in meta-analyses, Ottawa Health Research Institute Web site. 2012.
13.
Zurück zum Zitat Mantel N, Haenszel E. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel E. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
15.
Zurück zum Zitat Meyer PA, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–11.CrossRef Meyer PA, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–11.CrossRef
16.
Zurück zum Zitat Hong S, et al. Comparison of long-term outcome between doublet and triblet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. Oncology. 2011;80:107–17.PubMedCrossRef Hong S, et al. Comparison of long-term outcome between doublet and triblet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. Oncology. 2011;80:107–17.PubMedCrossRef
17.
Zurück zum Zitat Whelan JS, et al. Survival from high-grade localized extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomized controlled trials. Ann Oncol. 2012;23:1607–16.PubMedCentralPubMedCrossRef Whelan JS, et al. Survival from high-grade localized extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomized controlled trials. Ann Oncol. 2012;23:1607–16.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Marti C, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69:115–7.PubMed Marti C, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69:115–7.PubMed
19.
Zurück zum Zitat Pratt CB, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987;71:131–5.PubMed Pratt CB, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987;71:131–5.PubMed
20.
Zurück zum Zitat Bacci G, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Instituto Ortopedico Rizzoli according to the Instituto Ortopedico/Osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–27.PubMed Bacci G, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Instituto Ortopedico Rizzoli according to the Instituto Ortopedico/Osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–27.PubMed
21.
Zurück zum Zitat Lin F, et al. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 2011;7:270–5.PubMedCrossRef Lin F, et al. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 2011;7:270–5.PubMedCrossRef
22.
Zurück zum Zitat Kudawara I, et al. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother. 2013;25:41–8.PubMedCrossRef Kudawara I, et al. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother. 2013;25:41–8.PubMedCrossRef
23.
Zurück zum Zitat Bacci G, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori. 2004;90:478–84.PubMed Bacci G, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. Tumori. 2004;90:478–84.PubMed
24.
Zurück zum Zitat Bacci G, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at single institution. Cancer. 2006;106:1154–61.PubMedCrossRef Bacci G, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at single institution. Cancer. 2006;106:1154–61.PubMedCrossRef
25.
Zurück zum Zitat Durnali A, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.PubMedCrossRef Durnali A, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.PubMedCrossRef
26.
Zurück zum Zitat Smeland S, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488–94.PubMedCrossRef Smeland S, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488–94.PubMedCrossRef
27.
Zurück zum Zitat Goorin AM, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–80.PubMedCrossRef Goorin AM, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–80.PubMedCrossRef
28.
Zurück zum Zitat Yin K, et al. Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture. Exp Ther Med. 2012;4:889–94.PubMedCentralPubMed Yin K, et al. Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture. Exp Ther Med. 2012;4:889–94.PubMedCentralPubMed
Metadaten
Titel
Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials
verfasst von
Wenmei Su
Zhennan Lai
Fenping Wu
Yanming Lin
Yanli Mo
Zhixiong Yang
Jiayuan Wu
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0481-y

Weitere Artikel der Ausgabe 2/2015

Medical Oncology 2/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.